Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomes
Open Access
- 19 March 2014
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Abstract
The practice of traditional Chinese medicine (TCM) has a profound history in many Asian countries. TCM syndrome is a set of characteristic physical signs and symptoms shared by a group of patients. Syndrome diagnosis and treatment assignment according to the identified TCM syndrome is a long-held practice of Chinese medicine. Owing to its distinctive way of interpreting illness and administering care, medical practitioners not well educated in TCM theories and practices are generally incapable of giving out prescriptions for Chinese patent drugs. Currently, the existence of a multitude of Chinese patent drugs marked with largely identical indications is further complicating this situation. In this multicenter, randomized, controlled, double-blind, double-dummy clinical trial, in which we will use the comparative effectiveness research method, we will compare the efficacy of two commonly used Chinese patent medicines for angina patients diagnosed with qi deficiency and blood stasis syndrome. A total of 160 patients will be recruited and randomly assigned to receive either (1) QiShenYiQi dripping pills, Tongxinluo placebo and routine medication or (2) Tongxinluo capsules, QiShenYiQi placebo and routine medication. These treatment regimens will be carried out for 4 weeks, followed by a 10-day washout period and a 4-week crossover phase in which the treatments in the two patient groups will be exchanged. Patients will be allowed to choose symptoms that matter most to them and will be grouped accordingly. Patient-reported outcomes such as the Seattle Angina Questionnaire score and the 15-point Likert scale score will be measured and reported. The minimally clinical important difference will be calculated and used for efficacy assessment, and correspondence analysis will be performed to identify the best indications for each drug. The goal of the study is to establish a methodology for the precise identification of the characteristic indications for which a Chinese patent drug is most effective. The findings of this study will inform the practicality of the proposed evaluation method. Chinese clinical trials register Chi CTRTTRCC13003732Keywords
This publication has 9 references indexed in Scilit:
- Connotations and extensions of comparative effectiveness research and feasibility analysis for clinical evaluation in traditional Chinese medicineJournal of Chinese Integrative Medicine, 2012
- Minimal Important Difference (MID) of two commonly used outcome measures for foot problemsJournal of Foot and Ankle Research, 2010
- Comparative Effectiveness: Its Origin, Evolution, and Influence on Health CareJournal of Oncology Practice, 2009
- Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA PerspectiveValue in Health, 2007
- Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important changeHealth and Quality of Life Outcomes, 2006
- An integrated method to determine meaningful changes in health-related quality of lifeJournal of Clinical Epidemiology, 2004
- Beyond alpha: An empirical examination of the effects of different sources of measurement error on reliability estimates for measures of individual-differences constructs.Psychological Methods, 2003
- PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient PopulationsMedical Care, 2001
- Further Evidence Supporting an SEM-Based Criterion for Identifying Meaningful Intra-Individual Changes in Health-Related Quality of LifeJournal of Clinical Epidemiology, 1999